Mike has more than twenty years of experience spanning both research and development. Mike joined Latigo from Deciphera Pharmaceuticals, where during a 16-year tenure he served in positions of increasing responsibility, including vice president of Chemistry and Preclinical Development and, most recently, vice president of Chemical and Pharmaceutical Development. At Deciphera, he was integral to both the discovery and development of Qinlock® (ripretinib), and additional clinical candidates including rebastinib, altiratinib and vimseltinib. Prior to Deciphera, Mike was part of Pfizer Global Research and Development/Parke Davis Pharmaceutical. While there, he was an inventor of the clinical MEK inhibitor mirdametinib (PD-325901). Mike obtained a B.A. in Chemistry at the University of Kansas, a Ph.D. in Organic Chemistry from Indiana University, and completed his postdoctoral fellowship at the University of Pennsylvania.